Drug intelligence / Profile preview

tridolgosir

Development stage
Unknown
Lead developer
GlycoDesign
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Tridolgosir is a natural indolizidine alkaloid also known as swainsonine. It is a potent and reversible inhibitor of Golgi alpha-mannosidase II and lysosomal alpha-mannosidases. By inhibiting these enzymes involved in N-linked glycosylation of glycoproteins in the Golgi apparatus and lysosomes, tridolgosir disrupts the formation of complex carbohydrate structures on cell surfaces. This leads to reduced tumor cell aggressiveness and metastatic potential by decreasing highly branched carbohydrates that bind to lectin-phytohemagglutinin (L-PHA), while increasing “hybrid type” carbohydrates that may enhance immune recognition by lymphocytes and natural killer cells. Tridolgosir has demonstrated antiproliferative and immunomodulatory effects in preclinical studies but did not show anti-tumor activity in phase II clinical trials for renal cell carcinoma. It is also recognized as a plant toxin responsible for locoweed poisoning in livestock[1][2][3][4][5][6][7].

Brand names
tridolgosir
Other names
swainsonineswainsonine hydrochloridetridolgosir hydrochloride(1S,2R,8R,8aR)-octahydro-1,2,8-indolizinetriol
02

Targets

MAN2A1 (Golgi alpha-mannosidase II)MAN2B1 (Lysosomal alpha-mannosidase)

Beyond the preview

Go deeper on tridolgosir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tridolgosir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call